 |
Conference Summaries |
|
| CONFERENCE SUMMARY |
| AUA 2024 |
| Patrick J. Hensley, MD |
 |
|
| The American Urological Association Annual Meeting was held May 3-6, 2024, in San Antonio, Texas. The meeting included a number of notable plenaries, didactic, and clinical trial sessions dedicated to bladder cancer. |
|
|
|
|
|
|
| CONFERENCE SUMMARY |
| IBCG at AUA 2024 |
| Bogdana Schmidt, MD |
 |
|
| The International Bladder Cancer Group session at the AUA was held in San Antonio, Texas on May 5, 2024. The meeting was co-chaired by Drs. Janet Kukreja and Ashish Kamat. |
|
|
|
|
|
|
|
|
Conference Highlights |
|
| EAU 2024: Bladder Cancer Highlights |
 |
|
| Amanda Myers, MD |
|
The Rapid Fire Debates in Bladder Cancer, chaired by Prof. Kamat and Prof. Stenzl, at the European Association of Urology (EAU) 2024 annual meeting was the highlight of Friday’s program – the most attended event, a testament to its value and relevance.
|
|
|
|
|
|
| ASCO 2024: Bladder Cancer Highlights |
 |
|
| Shilpa Gupta, MD |
|
Enfortumab vedotin plus pembrolizumab showed nearly double median PFS and OS compared to platinum-based chemotherapy in advanced urothelial cancer, with improved patient-reported outcomes. The CheckMate 901 trial demonstrated better PFS and OS for nivolumab plus gemcitabine-cisplatin in patients with lymph node-only metastatic urothelial carcinoma. Additionally, interim results from the SURE trials indicated promising outcomes for sacituzumab govitecan, both alone and with pembrolizumab, in muscle-invasive bladder cancer.
|
|
|
|
|
|
|
|
| Gem/Doce in 2024: What is Next? |
 |
|
| Vignesh Packiam, MD |
|
Sequential intravesical gemcitabine and docetaxel (Gem/Doce) has been a notable advancement in the treatment of non-muscle invasive bladder cancer (NMIBC) since Michael O’Donnell developed this regimen in 2009.1 Following its initial publication in 2015, Gem/Doce has continued to gain traction in the urologic oncology community for various challenging situations.
|
|
|
|
|
|
| Racial Disparities in Bladder Cancer |
|
|
 |
|
| Patrick J. Hensley, MD & Stephen B. Williams, MD |
|
Despite White patients exhibiting nearly twice the incidence of bladder cancer compared to Black patients, there exist well-characterized disparate outcomes in bladder cancer-related mortality in Black patients.1-3 These poor outcomes are thought to be multifactorial, with likely contributors including poor access to healthcare, implicit racial bias, and inherent genomic differences between White and Black patients.
|
|
|
|
|
|
 |
SIU MASTERCLASS |
|
| Société Internationale d'Urologie (SIU) announced that IBCG will hold a a Masterclass in Non-Muscle Invasive Bladder Cancer at the 44th Congress to be held from October 23-26, 2024 in New Delhi, India. |
|
|
|
|
 |
UPCOMING MEETINGS |
|
- GSRGT-IBCG Joint Metting
TBD, Tampa, Florida
|
|
|
|
|
